新铜试剂 | 484-11-7

• 物质功能分类: 分析化学 - 分析试剂 - 常用分析试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 菲咯啉
• 中文名称: 新铜试剂
• 中文别名: 2,9-二甲基-1,10-菲咯啉；双喹哪啶；新亚铜试剂；2,9-二甲基-1,10-菲罗啉；Me2一phen；新亚铜试剂半水合物；2,9-二甲基-1,10-邻菲洛啉；2,9-二甲基-1,10-邻菲罗啉；2,9-二甲基-1,10-邻菲咯啉；2,9-二甲基-1,10-菲啰啉；9-二甲基-1,10-邻菲洛啉；2,9-二甲基邻菲啰啉；2.9-二甲基-1.10-菲罗啉
• 英文名称: 2,9-dimethyl-1,10-phenantroline
• 英文别名: 2.9-dimethyl-1,10-phenanthroline；2,9-dimethylphenanthroline；Neocuproine；dmp；2,9-dimethyl-10-phenanthroline；neocuprine；2,9-dimethyl-1,19-phenanthroline；2,9–dimethyl–1,10–phenanthroline；dmphen；neo；2,9-dimethyl-1,10-phenanthroline
• CAS: 484-11-7
• 化学式: C₁₄H₁₂N₂
• mdl: MFCD00004973
• 分子量: 208.263
• InChiKey: IYRGXJIJGHOCFS-UHFFFAOYSA-N

物化性质

• 熔点：
  159-164 °C
• 沸点：
  337.46°C (rough estimate)
• 密度：
  1.1345 (rough estimate)
• 溶解度：
  溶于甲醇，溶解度为0.1g/mL，澄清
• 稳定性/保质期：
  按规格使用和贮存，不会发生分解，并避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  29339990
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P280,P302+P352,P261,P304+P340,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封保存，并置于通风、干燥的地方，避免与氧化物接触。

SDS

Name:	2 9-Dimethyl-1 10-phenanthroline Material Safety Data Sheet
Synonym:	Neocuproine hemihydrat
CAS:	484-11-7

Section 1 - Chemical Product MSDS Name:2 9-Dimethyl-1 10-phenanthroline Material Safety Data Sheet
Synonym:Neocuproine hemihydrat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
484-11-7	2,9-Dimethyl-1,10-phenanthroline	100	207-601-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Light sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical aid if irritation develops or persists.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Reduce airborne dust and prevent scattering by moistening with water. Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Wash hands before eating. Use with adequate ventilation. Avoid contact with skin and eyes. Avoid ingestion and inhalation. Store protected from light.
Storage:
Store in a cool, dry place. Do not store in direct sunlight. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 484-11-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 160 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Soluble in water.
Specific Gravity/Density: Not available.
Molecular Formula: C14H12N2.0.5H2O
Molecular Weight: 225.1038

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 484-11-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,9-Dimethyl-1,10-phenanthroline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 484-11-7: 1
Canada
CAS# 484-11-7 is listed on Canada's DSL List.
CAS# 484-11-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 484-11-7 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

新铜试剂是一种用于铜测定的试剂，呈白色或黄褐色结晶状。它易溶于乙醇、正戊醇、异戊醇、正己醇、氯仿和苯，微溶于冷水。该试剂具有一定的刺激性。

新铜试剂结构中的氮原子具有还原性，在强氧化性环境下可能会发生氧化反应而失去稳定性。此外，新铜试剂中的氮原子可以接受质子形成阳离子，从而影响其稳定性。

应用

新铜试剂可用作测定亚铜的试剂，并可用于光度分析测定铜、超微血糖以及有机合成等领域。

2,9-二甲基-1，10-邻菲咯啉是菲咯啉基金属离子螯合剂，主要用于测定亚铜。其用途还包括光度分析测定铜、测定超微血糖和有机合成。

反应信息

• 作为反应物：
  描述：

  新铜试剂 在 盐酸 、 sodium molybdate 、 copper(II) nitrate trihydrate 作用下， 生成 1,10-邻二氮杂菲-2,9-二甲酸
  参考文献：
  名称：

  Design and in situ synthesis of a Cu-based porous framework featuring isolated double chain magnetic character

  摘要：

  利用原位配体形成法在水热条件下合成了一种铜基双链 MOF。这种双链 MOF 显示出与温度相关的铁磁性（长程有序）和反铁磁性（双链内）耦合。即使由于客体水分子的去除而导致结构坍塌，源自单个双链的磁性行为也几乎保持不变。

  DOI：

  10.1039/c1cc13418c
• 作为产物：
  描述：

  1,10-菲啰啉-2,9-二甲醛 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 新铜试剂
  参考文献：
  名称：

  Sequential multiple-target chemosensor: Co²⁺, Cu²⁺, PPi, and HSˉ discrimination by a bis(half-salamo)-type probe

  摘要：

  DOI：

  10.1080/10426507.2021.2012674
• 作为试剂：
  描述：

  溴二氟乙酸钾 、 5-phenylpent-1-en-3-yl 2,2,2-trifluoroacetate 在 新铜试剂 、 氰基硼氘化钠 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 以85 %的产率得到(E)-(6,6-difluorohex-3-en-1-yl-6-d)benzene
  参考文献：
  名称：

  二氟卡宾铜可实现催化二氟甲基化

  摘要：

  尽管二氟卡宾的合成用途广泛，但其高反应性严重限制了二氟卡宾在有机合成中的广泛应用。在这里，我们报道了二氟卡宾铜参与的催化偶联，代表了二氟甲基化反应的新模式。该方法允许使用 NaBH 3 CN 和低成本二氟卡宾前体 BrCF 2 CO 2 K 对各种容易获得的烯丙基/炔丙基亲电子试剂进行二氟甲基化，具有高成本效益、高立体和区域选择性以及高官能团耐受性，即使对于复杂的药物样分子也是如此。应用该方法可以有效合成具有药用意义的氘代二氟甲基化化合物。所得的二氟甲基化烯丙基和丙二烯基产物可以作为用于多种转化的通用合成子，使得该方法对于合成复杂的氟化结构具有吸引力。实验机理研究和计算计算表明，通过氢化硼对二氟卡宾铜(I)的亲核攻击形成二氟甲基铜(I)中间体是该反应的关键步骤。

  DOI：

  10.1021/jacs.4c04949

文献信息

• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2010017079A1

  公开（公告）日：2010-02-11

  The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Metal-, Photocatalyst-, and Light-Free Minisci C–H Alkylation of <i>N</i>-Heteroarenes with Oxalates
  作者：Jianyang Dong、Zhen Wang、Xiaochen Wang、Hongjian Song、Yuxiu Liu、Qingmin Wang

  DOI：10.1021/acs.joc.9b00972

  日期：2019.6.7

  for metal-, photocatalyst-, and light-free Minisci C–H alkylation reactions of N-heteroarenes with alkyl oxalates derived from primary, secondary, and tertiary alcohols. The protocol uses environmentally benign persulfate as a stoichiometric oxidant and does not require high temperatures or large excesses of either of the substrates, making the procedure suitable for late-stage C–H alkylation of complex

  在此，我们报告了N-杂芳烃与衍生自伯醇、仲醇和叔醇的草酸烷基酯的无金属、光催化剂和无光 Minisci C-H 烷基化反应的温和方案。该协议使用对环境无害的过硫酸盐作为化学计量氧化剂，不需要高温或任何一种底物的大量过量，使得该程序适用于复杂分子的后期 C-H 烷基化。值得注意的是，可以使用该协议对几种药物和天然产品进行功能化或制备，从而证明其实用性。
• [EN] BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY<br/>[FR] CONJUGUÉS BIOACTIFS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
  申请人：UNIV MASSACHUSETTS

  公开号：WO2017030973A1

  公开（公告）日：2017-02-23

  Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.

  本文提供的自递送寡核苷酸具有高效的RISC进入、最小的免疫反应和非靶效应、无需配方的高效细胞摄取，以及高效和特异的组织分布。
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。

表征谱图